This Program Project grant focuses on understanding the basic mechanisms that underlie diabetic gastroparesis and immediately translating those findings into new therapeutic solutions for our patients. This is important, as current therapeutic approaches for our patients with diabetic gastroparesis are largely ineffective. This highly productive Program Project is organized around 3 projects and 3 cores resulting in a tightly integrated Program Project. We will accomplish the overall objective of the Program Project by taking advantage of the cutting edge discovery work in all three Projects and making these discoveries immediately clinically relevant in Project 3. Project 1 utilizes a wide variety of innovative tools including next generation sequencing to determine the common unifying abnormality that leads to the diverse cellular changes seen in diabetic gastroparesis. Preliminary data suggest that macrophages are key to the development of diabetic gastroparesis and that modulation of macrophage subtypes and the heme oxygenase 1 pathway can reverse cellular injury and normalize gastric function. Project 2 will utilize state of the art tools to focus on the epigenetic control of neuronal nitric oxide synthase (Nos1, nNOS). Tissue-level reduction in Nos1 expression was the first specific form of diabetic enteric neuropathy described. Project 2 will examine a transcriptional/epigenetic network consisting of bone morphogenetic protein (Bmp)-Smad-Ep300/Crebbp histone acetyltransferases (HATs), hypoxia-inducible factor 1a (Hif1a)-Ep300/Crebbp HATs and insulin/insulin-like growth factor 1 (Igf1)-Ezh2 histone methyltransferase and proposes that this network regulates the pool of Nos1-expressing neurons in health and diabetic gastroparesis. Project 3 will continue to focus on understanding the mechanisms responsible for gastric emptying disturbances in diabetes and on developing highly novel management approaches for this condition including clinical trials. The Projects are supported by equally cutting edge cores. Core A will provide administrative support. Core B will support the epigenomic and transcriptomic experiments carried out by all three Projects by providing ChIP-seq, RNA-seq and DNA methylation expertise and tertiary bioinformatics analysis. Core C as a Physiological Characterization and Data Integration Core will provide service for all three Projects by performing gastric emptying and blood glucose assays in mice and mucosal ion flux in human biopsies, maintaining an Electronic Animal Research Record and developing and maintaining a platform for the integration of data collected in the Program Project. Together this highly integrated, synergistic and collaborative Program Project will mechanistically determine the underlying pathobiology of diabetic gastroparesis and use this information to devise and test therapies in patients in a very short bedside to patient time frame.

Public Health Relevance

This Program Project grant focuses on understanding the basic mechanisms that underlie diabetic gastroparesis, a complication of diabetes that causes the stomach to not work effectively. This is important as current therapeutic approaches for our patients are largely ineffective. We will take our discoveries and immediately run clinical trials s part of the Program Project to translate the findings into new therapeutic solutions for our patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK068055-14
Application #
9518831
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Hamilton, Frank A
Project Start
2004-09-30
Project End
2020-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
14
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Cipriani, Gianluca; Gibbons, Simon J; Miller, Katie E et al. (2018) Change in Populations of Macrophages Promotes Development of Delayed Gastric Emptying in Mice. Gastroenterology 154:2122-2136.e12
Desai, A; O'Connor, M; Neja, B et al. (2018) Reproducibility of gastric emptying assessed with scintigraphy in patients with upper GI symptoms. Neurogastroenterol Motil 30:e13365
Miller, K E; Bajzer, Ž; Hein, S S et al. (2018) High temporal resolution gastric emptying breath tests in mice. Neurogastroenterol Motil :e13333
Karakashev, Sergey; Zhu, Hengrui; Wu, Shuai et al. (2018) CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun 9:631
Rajan, Elizabeth; Al-Bawardy, Badr; Gostout, Christopher J et al. (2018) Endoscopic muscle biopsy sampling of the duodenum and rectum: a pilot survival study in a porcine model to detect myenteric neurons. Gastrointest Endosc 87:600-606
Zhong, Jian; Ye, Zhenqing; Lenz, Samuel W et al. (2017) Purification of nanogram-range immunoprecipitated DNA in ChIP-seq application. BMC Genomics 18:985
Parthasarathy, Gopanandan; Kudva, Yogish C; Low, Phillip A et al. (2017) Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial. J Clin Endocrinol Metab 102:398-406
Gibbons, Simon J; Grover, Madhusudan; Choi, Kyoung Moo et al. (2017) Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. PLoS One 12:e0187772
Hayashi, Yujiro; Toyomasu, Yoshitaka; Saravanaperumal, Siva Arumugam et al. (2017) Hyperglycemia Increases Interstitial Cells of Cajal via MAPK1 and MAPK3 Signaling to ETV1 and KIT, Leading to Rapid Gastric Emptying. Gastroenterology 153:521-535.e20
Camilleri, Michael; McCallum, Richard W; Tack, Jan et al. (2017) Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. Gastroenterology 153:1240-1250.e2

Showing the most recent 10 out of 134 publications